Literature DB >> 8627160

Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation.

P Poignard1, T Fouts, D Naniche, J P Moore, Q J Sattentau.   

Abstract

The spectrum of the anti-human immunodeficiency virus (HIV) neutralizing immune response has been analyzed by the production and characterization of monoclonal antibodies (mAbs) to the viral envelope glycoproteins, gp41 and gp120. Little is known, however, about the neutralization mechanism of these antibodies. Here we show that the binding of a group of neutralizing mAbs that react with regions of the gp120 molecule associated with and including the V2 and V3 loops, the C4 domain and supporting structures, induce the dissociation of gp120 from gp41 on cells infected with the T cell line-adapted HIV-1 molecular clone Hx10. Similar to soluble receptor-induced dissociation of gp120 from gp41, the antibody-induced dissociation is dose- and time-dependent. By contrast, mAbs binding to discontinuous epitopes overlapping the CD4 binding site do not induce gp120 dissociation, implying that mAb induced conformational changes in gp120 are epitope specific, and that HIV neutralization probably involves several mechanisms.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8627160      PMCID: PMC2192467          DOI: 10.1084/jem.183.2.473

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  72 in total

1.  Epitopes recognized by the neutralizing antibodies of an HIV-1-infected individual.

Authors:  A T Profy; P A Salinas; L I Eckler; N M Dunlop; P L Nara; S D Putney
Journal:  J Immunol       Date:  1990-06-15       Impact factor: 5.422

2.  CD4 immunoadhesin, but not recombinant soluble CD4, blocks syncytium formation by human immunodeficiency virus type 2-infected lymphoid cells.

Authors:  I Sekigawa; S M Chamow; J E Groopman; R A Byrn
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

3.  Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain.

Authors:  J D Laman; M M Schellekens; Y H Abacioglu; G K Lewis; M Tersmette; R A Fouchier; J P Langedijk; E Claassen; W J Boersma
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

4.  Dissociation of gp120 from HIV-1 virions induced by soluble CD4.

Authors:  J P Moore; J A McKeating; R A Weiss; Q J Sattentau
Journal:  Science       Date:  1990-11-23       Impact factor: 47.728

5.  Differences in the interaction of HIV-1 and HIV-2 with CD4.

Authors:  D J Looney; S Hayashi; M Nicklas; R R Redfield; S Broder; F Wong-Staal; H Mitsuya
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

6.  Soluble CD4 enhances simian immunodeficiency virus SIVagm infection.

Authors:  A Werner; G Winskowsky; R Kurth
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

7.  Functional interaction of constant and variable domains of human immunodeficiency virus type 1 gp120.

Authors:  R L Willey; E K Ross; A J Buckler-White; T S Theodore; M A Martin
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

8.  Correlation between kinetics of soluble CD4 interactions with HIV-1-Env-expressing cells and inhibition of syncytia formation: implications for mechanisms of cell fusion and therapy for AIDS.

Authors:  D S Dimitrov; K Hillman; J Manischewitz; R Blumenthal; H Golding
Journal:  AIDS       Date:  1992-03       Impact factor: 4.177

9.  Enhancement of SIV infection with soluble receptor molecules.

Authors:  J S Allan; J Strauss; D W Buck
Journal:  Science       Date:  1990-03-02       Impact factor: 47.728

10.  A chimeric mouse-human antibody that retains specificity for HIV gp120 and mediates the lysis of HIV-infected cells.

Authors:  R S Liou; E M Rosen; M S Fung; W N Sun; C Sun; W Gordon; N T Chang; T W Chang
Journal:  J Immunol       Date:  1989-12-15       Impact factor: 5.422

View more
  33 in total

1.  Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus.

Authors:  P D Kwong; R Wyatt; Q J Sattentau; J Sodroski; W A Hendrickson
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

2.  Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.

Authors:  C A Derdeyn; J M Decker; J N Sfakianos; X Wu; W A O'Brien; L Ratner; J C Kappes; G M Shaw; E Hunter
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design.

Authors:  Ralph Pantophlet; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

4.  Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells.

Authors:  A Valenzuela; J Blanco; B Krust; R Franco; A G Hovanessian
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

5.  Selective regulation of human immunodeficiency virus-infected CD4(+) lymphocytes by a synthetic immunomodulator leads to potent virus suppression in vitro and in hu-PBL-SCID mice.

Authors:  G M Bahr; E C Darcissac; N Castéran; C Amiel; C Cocude; M J Truong; J Dewulf; A Capron; Y Mouton
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

6.  Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors.

Authors:  Thomas J Ketas; Sophie Holuigue; Katie Matthews; John P Moore; Per Johan Klasse
Journal:  Virology       Date:  2011-10-22       Impact factor: 3.616

7.  Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans.

Authors:  I Mondor; S Ugolini; Q J Sattentau
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

8.  Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity.

Authors:  P W Parren; I Mondor; D Naniche; H J Ditzel; P J Klasse; D R Burton; Q J Sattentau
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

9.  Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research.

Authors:  Lindsay Wieczorek; Shelly J Krebs; Vaniambadi Kalyanaraman; Stephen Whitney; Sodsai Tovanabutra; Carlos G Moscoso; Eric Sanders-Buell; Constance Williams; Bonnie Slike; Sebastian Molnar; Vincent Dussupt; S Munir Alam; Agnes-Laurence Chenine; Tina Tong; Edgar L Hill; Hua-Xin Liao; Michael Hoelscher; Leonard Maboko; Susan Zolla-Pazner; Barton F Haynes; Michael Pensiero; Francine McCutchan; Shawyon Malek-Salehi; R Holland Cheng; Merlin L Robb; Thomas VanCott; Nelson L Michael; Mary A Marovich; Carl R Alving; Gary R Matyas; Mangala Rao; Victoria R Polonis
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

10.  Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies.

Authors:  M B Zwick; M Wang; P Poignard; G Stiegler; H Katinger; D R Burton; P W Parren
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.